Targeting NMDA in mental health has chalked wins but not universally, as shown by Sage Therapeutics Inc.’s failure of the placebo-controlled phase II Lightwave study testing dalzanemdor in Alzheimer's disease, which missed the primary outcome measure, another bit of bad luck from the company that was disclosed Oct. 8.
Randy Osborne is a staff writer for BioWorld Today, a publication focused on the biotechnology industry. With a talent for storytelling and a knack for creating new things, Randy's articles cover a wide range of topics within the biotech field, including company developments, clinical trials, and industry trends.